Juliet Gray

8PUBLICATIONS
103CO-AUTHORS
Cell physiologyOrthopaedicsHaematological tumoursSolid tumoursCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Mar 30, 2026
Reply to: Signal Worth Trusting-If We Can Reproduce It: Clarifying Overall Response Rate and Progression-Free Survival in BEACON Immuno.

Juliet Gray, Rebekah Weston, Simon Gates

|Dec 12, 2025
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial.

Juliet C Gray, Rebekah Weston, Cormac Owens

|Jul 08, 2025
Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial.

Holger N Lode, Nikolai Siebert, Dominique Valteau-Couanet

|Dec 26, 2024
Developing a 3D bone model of osteosarcoma to investigate cancer mechanisms and evaluate treatments.

Hannah L Smith, Stephen A Beers, Janos M Kanczler

Pageof 2